RT Journal Article
SR Electronic
T1 Dynamics of B-cell repertoires and emergence of cross-reactive responses in COVID-19 patients with different disease severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.13.20153114
DO 10.1101/2020.07.13.20153114
A1 Zachary Montague
A1 Huibin Lv
A1 Jakub Otwinowski
A1 William S. DeWitt
A1 Giulio Isacchini
A1 Garrick K. Yip
A1 Wilson W. Ng
A1 Owen Tak-Yin Tsang
A1 Meng Yuan
A1 Hejun Liu
A1 Ian A. Wilson
A1 J. S. Malik Peiris
A1 Nicholas C. Wu
A1 Armita Nourmohammad
A1 Chris Ka Pun Mok
YR 2021
UL http://medrxiv.org/content/early/2021/04/05/2020.07.13.20153114.abstract
AB COVID-19 patients show varying severity of the disease ranging from asymptomatic to requiring intensive care. Although a number of SARS-CoV-2 specific monoclonal antibodies have been identified, we still lack an understanding of the overall landscape of B-cell receptor (BCR) repertoires in COVID-19 patients. Here, we used high-throughput sequencing of bulk and plasma B-cells collected over multiple time points during infection to characterize signatures of B-cell response to SARS-CoV-2 in 19 patients. Using principled statistical approaches, we determined differential features of BCRs associated with different disease severity. We identified 38 significantly expanded clonal lineages shared among patients as candidates for specific responses to SARS-CoV-2. Using single-cell sequencing, we verified reactivity of BCRs shared among individuals to SARS-CoV-2 epitopes. Moreover, we identified natural emergence of a BCR with cross-reactivity to SARS-CoV-1 and SARS-CoV-2 in a number of patients. Our results provide important insights for development of rational therapies and vaccines against COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by DFG grant (SFB1310) on Predictability in Evolution (A.N., Z.M., J.O., G.I.), the Max Planck Society through MPRG funding (A.N., Z.M., J.O., G.I.), Department of Physics at the University of Washington (A.N., Z.M.), Royalty Research Fund at the University of Washington (A.N., Z.M.), NIH NIAID F31AI150163 (WSD), Calmette and Yersin scholarship from the Pasteur International Network Association (H.L.), Bill and Melinda Gates Foundation OPP1170236 (I.A.W.), a startup fund at the University of Illinois at Urbana-Champaign (N.C.W.), US National Institutes of Health (contract no. HHSN272201400006C) (J.S.M.P), National Natural Science Foundation of China (NSFC)/Research Grants Council (RGC) Joint Research Scheme (N_HKU737/18) (C.K.P.M. and J.S.M.P) and the Research Grants Council of the Hong Kong Special Administrative Region, China (Project no. T11-712/19-N) (J.S.M.P). We acknowledge the support of the clinicians who facilitated this study, including Drs Wai Shing Leung, Jacky Man Chun Chan, Thomas Shiu Hong Chik, Chris Yau Chung Choi, John Yu Hong Chan, Daphne Pui-Lin Lau, and Ying Man Ho; the dedicated clinical team at Infectious Diseases Centre, Princess Margaret Hospital, Hospital Authority of Hong Kong; and the patients who kindly consented to participate in this investigation. We also thank the Center for PanorOmic Sciences (CPOS), LKS Faculty of Medicine, and University of Hong Kong for their support on next-generation sequencing and acknowledge the use of the computational infrastructure provided by the Hyak supercomputer system funded by the student technology fund (STF) at the University of Washington.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review board of the Hong Kong West Cluster of the Hospital Authority of Hong Kong (approval number: UW20-169).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes BCR repertoire data and single-cell data can be accessed through: https://www.ncbi.nlm.nih.gov/bioproject/PRJNA645245 https://www.ncbi.nlm.nih.gov/bioproject/PRJNA679920 All codes for data processing and statistical analysis can be found at: https://github.com/StatPhysBio/covid-BCR https://www.ncbi.nlm.nih.gov/bioproject/PRJNA645245 https://www.ncbi.nlm.nih.gov/bioproject/PRJNA679920